Results 161 to 170 of about 541,048 (356)
What's New? Human papillomavirus (HPV) testing has revolutionized cervical cancer screening. Nonetheless, its optimal use for distinguishing between high‐ and low‐risk infections to leverage screening benefits remains to be established. Here, long‐term HPV genotype‐specific risk of precancerous cervical intraepithelial neoplasia grade 2 or higher was ...
Maija Vahteristo +6 more
wiley +1 more source
Are obstetrics and gynecology residents sexually satisfied? [PDF]
Kamat N, Kingsberg S, Kelley E.
europepmc +1 more source
What's New? Adult T‐cell leukemia/lymphoma (ATL) is a rare and aggressive malignancy caused by human T‐cell leukemia virus type 1 (HTLV‐1). The authors comprehensively analyzed the epidemiological and clinical features of ATL over a 30‐year period in French Guiana, a region with high HTLV‐1 endemicity and a multiethnic population.
Jill‐Léa Ramassamy +16 more
wiley +1 more source
The Necessity of Diversity, Equity and Inclusion Training for Obstetrics and Gynecology: A Department-Wide Needs Assessment of an Academic Obstetrics and Gynecology Department. [PDF]
DeGaia AGR, Darivemula S, Young OM.
europepmc +1 more source
What's New? Offering the option of self‐sampling in cervical cancer screening programs could increase participation. However, it could also prompt participants to switch from clinician‐collecting sampling, which has demonstrated higher testing sensitivity and lower loss to follow‐up.
Sylvia Kaljouw +4 more
wiley +1 more source
Editorial: Insights in obstetrics and gynecology: 2023. [PDF]
Cohen SM, Yagel S.
europepmc +1 more source
What's New? CATCH is a prospective precision oncology registry trial that harnesses whole‐genome/exome‐ and RNA‐sequencing to enable actionable biomarker detection in metastatic breast cancer patients of any subtype. The data of the first 412 consecutive patients with completed follow‐up in this real‐world, single‐center patient cohort provide robust ...
Mario Hlevnjak +31 more
wiley +1 more source

